A Randomized, Double-Blind, Placebo Controlled, Single and Multiple Dosing, Dose-Escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect After Oral Administration of HGR4113 in Healthy Subjects
Latest Information Update: 25 Mar 2024
At a glance
- Drugs HGR 4113 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Glaceum
Most Recent Events
- 18 Mar 2024 Planned number of patients changed from 48 to 40.
- 18 Mar 2024 Planned End Date changed from 30 Jun 2024 to 31 Jan 2025.
- 18 Mar 2024 Planned primary completion date changed from 30 Jun 2024 to 31 Jul 2024.